Dihydroalprenolol

Dihydroalprenolol is a beta-adrenergic receptor antagonist, commonly known as a beta blocker. It is a derivative of alprenolol, which is used in the treatment of hypertension and angina pectoris. Dihydroalprenolol is primarily used in research settings to study beta-adrenergic receptors due to its high affinity for these receptors.
Chemical Structure and Properties[edit]
Dihydroalprenolol is a synthetic compound with the chemical formula C15H25NO2. It is a racemic mixture of two enantiomers. The compound is characterized by its ability to bind to beta-adrenergic receptors, inhibiting the action of endogenous catecholamines like epinephrine and norepinephrine.
Mechanism of Action[edit]
As a beta blocker, dihydroalprenolol works by blocking the beta-adrenergic receptors in the heart and vascular system. This action leads to a decrease in heart rate, myocardial contractility, and blood pressure. By inhibiting these receptors, dihydroalprenolol reduces the effects of sympathetic nervous system stimulation.
Uses in Research[edit]
Dihydroalprenolol is not typically used in clinical practice but is valuable in pharmacological research. It is often used in radioligand binding assays to study the density and affinity of beta-adrenergic receptors in various tissues. This research helps in understanding the role of these receptors in different physiological and pathological conditions.
Pharmacokinetics[edit]
The pharmacokinetics of dihydroalprenolol involve its absorption, distribution, metabolism, and excretion. It is well-absorbed after oral administration and undergoes extensive first-pass metabolism in the liver. The metabolites are primarily excreted via the kidneys.
Side Effects and Precautions[edit]
As a research compound, dihydroalprenolol is not typically associated with clinical side effects. However, beta blockers in general can cause bradycardia, hypotension, fatigue, and dizziness. Caution is advised when interpreting research data, as these effects can influence experimental outcomes.
Related Compounds[edit]
Dihydroalprenolol is related to other beta blockers such as propranolol, metoprolol, and atenolol. These compounds share similar mechanisms of action but differ in their pharmacokinetic profiles and clinical uses.
See Also[edit]
References[edit]
External Links[edit]
-
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
